Cannabinoid Receptor Blockade Did Not Explain Every Effect of a JNK Inhibitor
A JNK inhibitor’s pain-related mechanism changed with sex and dose in mice. Results blocked by cannabinoid antagonists at one condition did not explain all effects at higher doses.
A signaling inhibitor was the test drug
Researchers tested SU3327 using formalin pain behavior, temperature and motor assessments in male and female mice. They also examined spinal gene expression and used CB1, CB2 and opioid antagonists. SU3327 is not THC or a cannabis constituent.
The receptor pattern was conditional
Lower effective doses in males were sensitive to CB1 and CB2 blockade. At a higher dose, the male antinociceptive effect was not blocked in the same way; female findings supported a different CB2-related pattern. Higher-dose motor suppression and hypothermia added interpretive concerns.
Less pain behavior needs context
Reduced movement can complicate interpretation of a behavioral pain endpoint. Antagonist experiments help investigate pathways, but drug selectivity and unidentified targets remain limitations. The paper cannot establish that cannabis would reproduce SU3327’s effects, or that females and males have a universal opposite THC response. It supports attaching dose, sex, endpoint and receptor-control evidence to a mechanistic claim rather than assigning every effect to the cannabinoid system.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CB2 receptors in female, and CB1/CB2 receptors in male mice in an inflammatory pain model. Brain research bulletin (2021). DOI: 10.1016/j.brainresbull.2021.09.004.
